UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

Program Number	2025 1088-18
Program	Prior Authorization-Notification
Medication	Cequa™ (cyclosporine 0.09% ophthalmic solution)*, Miebo™ (perfluorohexyloctane), Restasis® (cyclosporine 0.05% ophthalmic emulsion), Restasis MultiDose® (cyclosporine 0.05% ophthalmic emulsion)*, Tryptyr® (acoltremon ophthalmic solution)*, Tyrvaya™ (varenicline nasal spray), Vevye™ (cyclosporine 0.1%)*, Xiidra® (lifitegrast 5% ophthalmic solution)
P&T Approval Date	3/2006, 3/2007, 8/2008, 8/2009, 9/2010, 3/2011, 2/2012, 2/2013, 4/2014, 4/2015, 3/2016, 12/2016, 9/2017, 9/2018, 3/2019, 4/2020, 4/2021, 12/2021, 12/2022, 9/2023, 3/2024, 7/2024, 7/2025, 9/2025
Effective Date	1/17/2026

1. Background:

Cequa (cyclosporine 0.09% ophthalmic solution)*, Restasis (cyclosporine 0.05% ophthalmic emulsion) and Restasis MultiDose (cyclosporine 0.05% ophthalmic emulsion)*, are indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.
Miebo (perfluorohexyloctane), Tryptyr (acoltremon ophthalmic solution)*, Tyrvaya (varenicline nasal spray), Vevye (cyclosporine 0.1%)* and Xiidra (lifitegrast 5% ophthalmic solution) are indicated for the treatment of the signs and symptoms of dry eye disease.

2. Coverage Criteria[a]:

A. Initial Authorization

1. **Cequa*, Miebo, Restasis, Restasis MultiDose*, Tryptyr*, Tyrvaya, Vevye* or Xiidra** will be approved based on the following criterion:

   a. Diagnosis of **one** of the following:

      1) Moderate to severe keratoconjunctivitis sicca
      2) Dry Eye Disease

-AND-

   b. Medication will not be used in combination with another prescription product for dry eye disease or keratoconjunctivitis sicca

Authorization will be issued for 12 months.

B. Reauthorization

1. **Cequa*, Miebo, Restasis, Restasis MultiDose*, Tryptyr*, Tyrvaya, Vevye*** or **Xiidra** will be approved based on the following criterion:

a. Patient has demonstrated clinically significant improvement with therapy

-AND-

b. Medication will not be used in combination with another prescription product for dry eye disease or keratoconjuctivitis sicca

Authorization will be issued for 12 months.

[a] State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

*Cequa, Restasis MultiDose, Tryptyr and Vevye are typically excluded from coverage.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may be in place.
- Prior Authorization – Medical Necessity may be in place.

4. References:

1. Cequa [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc; December 2022
2. Miebo [package insert]. Bridgewater, NJ: Bausch & Lomb Americas Inc; January 2024.
3. Restasis [package insert]. North Chicago, IL: AbbVie Inc.; September 2024
4. Restasis MultiDose [package insert]. North Chicago, IL: AbbVie Inc.; September 2024
5. Tyrvaya [package insert]. Princeton NJ: Oyster Point Pharma, Inc; February 2024.
6. Tryptyr [package insert]. Fort Worth TX: Alcon Laboratories; May 2025.
7. Vevye [package insert]. Nashville, TN: Harrow Eye, LLC; November 2023.
8. Xiidra [package insert]. Bridgewater, NJ: Bausch & Lomb Americas Inc; December 2023.
9. American Academy of Ophthalmology. Dry Eye Syndrome Preferred Practice Pattern 2023.

Program	Notification – Dry Eye Disease
Change Control	
4/2014	No changes to criteria. Updated references.
4/2015	Updating authorization criteria to 6 months and reauthorization criteria to 12 months to align with prior authorization-medical necessity criteria
3/2016	Removed the Prior Authorization-Medical Necessity program language.
12/2016	Updated criteria to allow for Dry Eye Disease. Added Xiidra to criteria. Changed name of criteria to Dry Eye Disease.
9/2017	Annual review. Administrative updates. Added Restasis MultiDose. Updated references.
9/2018	Annual review. Administrative updates and updated references.
12/2018	Administrative change to add statement regarding use of automated processes.
3/2019	Added Cequa and updated references.
4/2020	Annual review. Removed extemporaneously compounded cyclosporine criteria. Updated references.

4/2021	Annual review. Updated references.
12/2021	Added Tyrvaya.
12/2022	Annual review. Added state mandate language. Updated references.
9/2023	Added Miebo and Vevye. Updated references.
3/2024	Updated initial authorization to 12 months. Updated references.
7/2024	Added concomitant therapy language. Updated references.
7/2025	Annual review. Updated references.
9/2025	Added Tryptyr.